Tengion Launches Third Phase 2 Clinical Trial Of Regenerated Human Bladder

Tengion, Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced it is initiating its third Phase 2 multi-center clinical trial of its Neo-Bladder Augment derived from a patient’s own (autologous) cells. The U.S.-based study is being conducted at five hospitals in 10 adult patients with non-neurogenic over-active bladder (OAB) who are intolerant or not adequately responsive to medical therapy.

More: continued here

Filed under: Clinical Trials on January 4th, 2008